{"pmid":32375002,"title":"Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery.","text":["Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery.","Lipid nanoparticle (LNP) packaged mRNA vaccines have been deployed against infectious diseases such as COVID-19, yet their structural features remain unclear. Cholesterol, a major constituent within LNPs, contributes to their morphology that influences gene delivery. Herein, we examine the structure of LNPs containing cholesterol derivatives using electron microscopy, differential scanning calorimetry, and membrane fluidity assays. LNPs formulated with C24 alkyl derivatives of cholesterol show polymorphic shape and various degrees of multilamellarity and lipid partitioning, likely due to phase separation. The addition of methyl and ethyl groups to C24 alkyl tail of cholesterol backbone induces multilamellarity (>50% increase compared to cholesterol) while the addition of double bond induces lipid partitioning (>90% increase compared to cholesterol. LNPs with multilamellar and faceted structures, as well as lamellar lipid phase, showed higher gene transfection. Unraveling the structure of mRNA-LNPs can enable their rational design towards enhanced gene delivery.","Nano Lett","Eygeris, Yulia","Patel, Siddharth","Jozic, Antony","Sahay, Gaurav","32375002"],"abstract":["Lipid nanoparticle (LNP) packaged mRNA vaccines have been deployed against infectious diseases such as COVID-19, yet their structural features remain unclear. Cholesterol, a major constituent within LNPs, contributes to their morphology that influences gene delivery. Herein, we examine the structure of LNPs containing cholesterol derivatives using electron microscopy, differential scanning calorimetry, and membrane fluidity assays. LNPs formulated with C24 alkyl derivatives of cholesterol show polymorphic shape and various degrees of multilamellarity and lipid partitioning, likely due to phase separation. The addition of methyl and ethyl groups to C24 alkyl tail of cholesterol backbone induces multilamellarity (>50% increase compared to cholesterol) while the addition of double bond induces lipid partitioning (>90% increase compared to cholesterol. LNPs with multilamellar and faceted structures, as well as lamellar lipid phase, showed higher gene transfection. Unraveling the structure of mRNA-LNPs can enable their rational design towards enhanced gene delivery."],"journal":"Nano Lett","authors":["Eygeris, Yulia","Patel, Siddharth","Jozic, Antony","Sahay, Gaurav"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32375002","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1021/acs.nanolett.0c01386","locations":["Lipid"],"e_drugs":["Cholesterol","Lipids"],"topics":["Mechanism"],"weight":1,"_version_":1666138496517013504,"score":9.490897,"similar":[{"pmid":32366816,"title":"An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.","text":["An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.","The first outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, Hubei Province, China, in late 2019. The subsequent COVID-19 pandemic rapidly affected the health and economy of the world. The global approach to the pandemic was to isolate populations to reduce the spread of this deadly virus while vaccines began to be developed. In March 2020, the first phase I clinical trial of a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine, mRNA-1273, which encodes the spike protein (S protein) of SARS-CoV-2, began in the United States (US). The production of mRNA-based vaccines is a promising recent development in the production of vaccines. However, there remain significant challenges in the development and testing of vaccines as rapidly as possible to control COVID-19, which requires international collaboration. This review aims to describe the background to the rationale for the development of mRNA-based SARS-CoV-2 vaccines and the current status of the mRNA-1273 vaccine.","Med Sci Monit","Wang, Fuzhou","Kream, Richard M","Stefano, George B","32366816"],"abstract":["The first outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, Hubei Province, China, in late 2019. The subsequent COVID-19 pandemic rapidly affected the health and economy of the world. The global approach to the pandemic was to isolate populations to reduce the spread of this deadly virus while vaccines began to be developed. In March 2020, the first phase I clinical trial of a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine, mRNA-1273, which encodes the spike protein (S protein) of SARS-CoV-2, began in the United States (US). The production of mRNA-based vaccines is a promising recent development in the production of vaccines. However, there remain significant challenges in the development and testing of vaccines as rapidly as possible to control COVID-19, which requires international collaboration. This review aims to describe the background to the rationale for the development of mRNA-based SARS-CoV-2 vaccines and the current status of the mRNA-1273 vaccine."],"journal":"Med Sci Monit","authors":["Wang, Fuzhou","Kream, Richard M","Stefano, George B"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32366816","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.12659/MSM.924700","locations":["Wuhan","Hubei","China","United States","US"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"e_drugs":["Lipids"],"topics":["Treatment"],"weight":1,"_version_":1666138496124846081,"score":522.6365},{"pmid":32191676,"title":"Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?","text":["Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?","BACKGROUND: Viral infectivity depends on interactions between components of the host cell plasma membrane and the virus envelope. Here we review strategies that could help stem the advance of the SARS-COV-2 epidemic. METHODS AND RESULTS: We focus on the role of lipid structures, such as lipid rafts and cholesterol, involved in the process, mediated by endocytosis, by which viruses attach to and infect cells. Previous studies have shown that many naturally derived substances, such as cyclodextrin and sterols, could reduce the infectivity of many types of viruses, including the coronavirus family, through interference with lipid-dependent attachment to human host cells. CONCLUSIONS: Certain molecules prove able to reduce the infectivity of some coronaviruses, possibly by inhibiting viral lipid-dependent attachment to host cells. More research into these molecules and methods would be worthwhile as it could provide insights the mechanism of transmission of SARS-COV-2 and, into how they could become a basis for new antiviral strategies.","Acta Biomed","Baglivo, Mirko","Baronio, Manuela","Natalini, Giuseppe","Beccari, Tommaso","Chiurazzi, Pietro","Fulcheri, Ezio","Petralia, Paolo Pietro","Michelini, Sandro","Fiorentini, Giovanni","Miggiano, Giacinto Abele","Morresi, Assunta","Tonini, Gerolamo","Bertelli, Matteo","32191676"],"abstract":["BACKGROUND: Viral infectivity depends on interactions between components of the host cell plasma membrane and the virus envelope. Here we review strategies that could help stem the advance of the SARS-COV-2 epidemic. METHODS AND RESULTS: We focus on the role of lipid structures, such as lipid rafts and cholesterol, involved in the process, mediated by endocytosis, by which viruses attach to and infect cells. Previous studies have shown that many naturally derived substances, such as cyclodextrin and sterols, could reduce the infectivity of many types of viruses, including the coronavirus family, through interference with lipid-dependent attachment to human host cells. CONCLUSIONS: Certain molecules prove able to reduce the infectivity of some coronaviruses, possibly by inhibiting viral lipid-dependent attachment to host cells. More research into these molecules and methods would be worthwhile as it could provide insights the mechanism of transmission of SARS-COV-2 and, into how they could become a basis for new antiviral strategies."],"journal":"Acta Biomed","authors":["Baglivo, Mirko","Baronio, Manuela","Natalini, Giuseppe","Beccari, Tommaso","Chiurazzi, Pietro","Fulcheri, Ezio","Petralia, Paolo Pietro","Michelini, Sandro","Fiorentini, Giovanni","Miggiano, Giacinto Abele","Morresi, Assunta","Tonini, Gerolamo","Bertelli, Matteo"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32191676","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.23750/abm.v91i1.9402","e_drugs":["Cyclodextrins","Cholesterol","Sterols","Lipids"],"topics":["Mechanism","Transmission"],"weight":1,"_version_":1666138490565296128,"score":521.9161},{"pmid":32457038,"title":"Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.","text":["Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.","The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the death of more than 328,000 persons worldwide in the first 5 months of 2020. Herculean efforts to rapidly design and produce vaccines and other antiviral interventions are ongoing. However, newly evolving viral mutations, the prospect of only temporary immunity, and a long path to regulatory approval pose significant challenges and call for a common, readily available and inexpensive treatment. Strategic drug repurposing combined with rapid testing of established molecular targets could provide a pause in disease progression. SARS-CoV-2 shares extensive structural and functional conservation with SARS-CoV-1 including engagement of the same host cell receptor (ACE2) localized in cholesterol-rich microdomains. These lipid-enveloped viruses encounter the endosomal/lysosomal host compartment in a critical step of infection and maturation. Niemann-Pick type C (NP-C) disease is a rare, monogenic neurodegenerative disease caused by deficient efflux of lipids from the late endosome/lysosome (LE/L). The NP-C disease-causing gene (NPC1) has been strongly associated with viral infection, as a filovirus receptor (e.g., Ebola) and through LE/L lipid trafficking. This suggests NPC1 inhibitors or NP-C disease mimetics could serve as anti-SARS-CoV-2 agents. Fortunately, there are such clinically approved molecules that elicit antiviral activity in pre-clinical studies, without causing NP-C disease. Inhibition of NPC1 may impair viral SARS-CoV-2 infectivity via several lipid-dependent mechanisms, which disturb the microenvironment optimum for viral infectivity. We suggest that known mechanistic information on NPC1 could be utilized to identify existing and future drugs to treat COVID-19.","J Lipid Res","Sturley, Stephen","Rajakumar, Tamayanthi","Hammond, Natalie","Higaki, Katsumi","Marka, Zsuzsa","Marka, Szabolcs","Munkacsi, Andrew","32457038"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the death of more than 328,000 persons worldwide in the first 5 months of 2020. Herculean efforts to rapidly design and produce vaccines and other antiviral interventions are ongoing. However, newly evolving viral mutations, the prospect of only temporary immunity, and a long path to regulatory approval pose significant challenges and call for a common, readily available and inexpensive treatment. Strategic drug repurposing combined with rapid testing of established molecular targets could provide a pause in disease progression. SARS-CoV-2 shares extensive structural and functional conservation with SARS-CoV-1 including engagement of the same host cell receptor (ACE2) localized in cholesterol-rich microdomains. These lipid-enveloped viruses encounter the endosomal/lysosomal host compartment in a critical step of infection and maturation. Niemann-Pick type C (NP-C) disease is a rare, monogenic neurodegenerative disease caused by deficient efflux of lipids from the late endosome/lysosome (LE/L). The NP-C disease-causing gene (NPC1) has been strongly associated with viral infection, as a filovirus receptor (e.g., Ebola) and through LE/L lipid trafficking. This suggests NPC1 inhibitors or NP-C disease mimetics could serve as anti-SARS-CoV-2 agents. Fortunately, there are such clinically approved molecules that elicit antiviral activity in pre-clinical studies, without causing NP-C disease. Inhibition of NPC1 may impair viral SARS-CoV-2 infectivity via several lipid-dependent mechanisms, which disturb the microenvironment optimum for viral infectivity. We suggest that known mechanistic information on NPC1 could be utilized to identify existing and future drugs to treat COVID-19."],"journal":"J Lipid Res","authors":["Sturley, Stephen","Rajakumar, Tamayanthi","Hammond, Natalie","Higaki, Katsumi","Marka, Zsuzsa","Marka, Szabolcs","Munkacsi, Andrew"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32457038","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1194/jlr.R120000851","keywords":["cholesterol","cholesterol/trafficking","dyslipidemias","ldl/metabolism","lipase/lysosomal","niemann-pick disease","sars-cov-2","storage diseases","coronavirus","drug repurposing","lysosomal storage disease","pandemic"],"e_drugs":["Cholesterol","Lipids"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668141322613030913,"score":444.08795},{"pmid":32430154,"title":"Hypolipidemia is associated with the severity of COVID-19.","text":["Hypolipidemia is associated with the severity of COVID-19.","BACKGROUND: Many patients with coronavirus disease 2019 (COVID-19) suffer multiple organ dysfunctions. However, whether patients develop dyslipidemia is unknown. OBJECTIVE: In this study, we aimed to investigate the pathological alterations of low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and total cholesterol (TC) in COVID-19 patients and their relationships with the disease severity. METHODS: A retrospective study was performed to examine serum levels of LDL-c, HDL-c, and TC on 597 COVID-19 patients (mild: 394; severe, 171; critical: 32) who were hospitalized in our center between February 1 and March 3, 2020. Age- and gender-matched normal subjects (n = 50) who had routine laboratory lipid tests between October 1 and November 1, 2019 in our center were included as the control group. RESULTS: LDL-c and TC levels were significantly lower in COVID-19 patients as compared with normal subjects (P < .001). There were significant and gradual decreases in levels of LDL-c (median (IQR) in mg/dL, mild: 91 (76, 104); severe: 86 (69, 102); critical: 69 (48, 81); P < .02) and TC (mild: 173 (148, 203); severe: 167 (138, 197); critical: 125 (95, 162); P < .05) across all three groups. HDL-c levels only decreased significantly in critical cases as compared with levels in mild and severe cases. LDL-c and TC levels inversely correlated with C-reactive protein and interleukin-6, and positively correlated with the number of lymphocytes in patients. CONCLUSIONS: Development of hypolipidemia begins in patients with mild symptoms. It progressively becomes worse in an association with the disease severity.","J Clin Lipidol","Wei, Xiuqi","Zeng, Wenjuan","Su, Jingyu","Wan, Huimin","Yu, Xinqin","Cao, Xiaoling","Tan, Wenbin","Wang, Hui","32430154"],"abstract":["BACKGROUND: Many patients with coronavirus disease 2019 (COVID-19) suffer multiple organ dysfunctions. However, whether patients develop dyslipidemia is unknown. OBJECTIVE: In this study, we aimed to investigate the pathological alterations of low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and total cholesterol (TC) in COVID-19 patients and their relationships with the disease severity. METHODS: A retrospective study was performed to examine serum levels of LDL-c, HDL-c, and TC on 597 COVID-19 patients (mild: 394; severe, 171; critical: 32) who were hospitalized in our center between February 1 and March 3, 2020. Age- and gender-matched normal subjects (n = 50) who had routine laboratory lipid tests between October 1 and November 1, 2019 in our center were included as the control group. RESULTS: LDL-c and TC levels were significantly lower in COVID-19 patients as compared with normal subjects (P < .001). There were significant and gradual decreases in levels of LDL-c (median (IQR) in mg/dL, mild: 91 (76, 104); severe: 86 (69, 102); critical: 69 (48, 81); P < .02) and TC (mild: 173 (148, 203); severe: 167 (138, 197); critical: 125 (95, 162); P < .05) across all three groups. HDL-c levels only decreased significantly in critical cases as compared with levels in mild and severe cases. LDL-c and TC levels inversely correlated with C-reactive protein and interleukin-6, and positively correlated with the number of lymphocytes in patients. CONCLUSIONS: Development of hypolipidemia begins in patients with mild symptoms. It progressively becomes worse in an association with the disease severity."],"journal":"J Clin Lipidol","authors":["Wei, Xiuqi","Zeng, Wenjuan","Su, Jingyu","Wan, Huimin","Yu, Xinqin","Cao, Xiaoling","Tan, Wenbin","Wang, Hui"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32430154","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jacl.2020.04.008","keywords":["covid-19","cholesterol","hdl-c","ldl-c","sars-cov-2"],"e_drugs":["Lipids","Cholesterol"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667342288418766848,"score":422.57642},{"pmid":32323974,"pmcid":"PMC7202245","title":"Rapid and Sensitive Detection of anti-SARS-CoV-2 IgG, Using Lanthanide-Doped Nanoparticles-Based Lateral Flow Immunoassay.","text":["Rapid and Sensitive Detection of anti-SARS-CoV-2 IgG, Using Lanthanide-Doped Nanoparticles-Based Lateral Flow Immunoassay.","The outbreak of 2019 coronavirus disease (COVID-19) has been a challenge for hospital laboratories because of the huge number of samples that must be tested for the presence of the causative pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Simple and rapid immunodiagnostic methods are urgently needed to identify positive cases. Here we report the development of a rapid and sensitive lateral flow immunoassay (LFIA) that uses lanthanide-doped polysterene nanoparticles (LNPs) to detect anti-SARV-CoV-2 IgG in human serum. A recombinant nucleocapsid phosphoprotein of SARS-CoV-2 was dispensed onto a nitrocellulose membrane to capture specific IgG. Mouse anti-human IgG antibody was labeled with self-assembled LNPs that served as a fluorescent reporter. A 100-muL aliquot of serum samples (1:1000 dilution) was used for this assay and the whole detection process took 10 min. The results of the validation experiment met the requirements for clinical diagnostic reagents. A value of 0.0666 was defined as the cutoff value by assaying 51 normal samples. We tested 7 samples that were positive by reverse-transcription (RT-)PCR and 12 that were negative but clinically suspicious for the presence of anti-SARS-CoV-2 IgG. One of the negative samples was determined to be SARS-CoV-2 IgG positive, while the results for the other samples were consistent with those obtained by RT-PCR. Thus, this assay can achieve rapid and sensitive detection of anti-SARS-CoV-2 IgG in human serum and allow positive identification in suspicious cases; it can also be useful for monitoring the progression COVID-19 and evaluating patients' response to treatment.","Anal Chem","Chen, Zhenhua","Zhang, Zhigao","Zhai, Xiangming","Li, Yongyin","Lin, Li","Zhao, Hui","Bian, Lun","Li, Peng","Yu, Lei","Wu, Yingsong","Lin, Guanfeng","32323974"],"abstract":["The outbreak of 2019 coronavirus disease (COVID-19) has been a challenge for hospital laboratories because of the huge number of samples that must be tested for the presence of the causative pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Simple and rapid immunodiagnostic methods are urgently needed to identify positive cases. Here we report the development of a rapid and sensitive lateral flow immunoassay (LFIA) that uses lanthanide-doped polysterene nanoparticles (LNPs) to detect anti-SARV-CoV-2 IgG in human serum. A recombinant nucleocapsid phosphoprotein of SARS-CoV-2 was dispensed onto a nitrocellulose membrane to capture specific IgG. Mouse anti-human IgG antibody was labeled with self-assembled LNPs that served as a fluorescent reporter. A 100-muL aliquot of serum samples (1:1000 dilution) was used for this assay and the whole detection process took 10 min. The results of the validation experiment met the requirements for clinical diagnostic reagents. A value of 0.0666 was defined as the cutoff value by assaying 51 normal samples. We tested 7 samples that were positive by reverse-transcription (RT-)PCR and 12 that were negative but clinically suspicious for the presence of anti-SARS-CoV-2 IgG. One of the negative samples was determined to be SARS-CoV-2 IgG positive, while the results for the other samples were consistent with those obtained by RT-PCR. Thus, this assay can achieve rapid and sensitive detection of anti-SARS-CoV-2 IgG in human serum and allow positive identification in suspicious cases; it can also be useful for monitoring the progression COVID-19 and evaluating patients' response to treatment."],"journal":"Anal Chem","authors":["Chen, Zhenhua","Zhang, Zhigao","Zhai, Xiangming","Li, Yongyin","Lin, Li","Zhao, Hui","Bian, Lun","Li, Peng","Yu, Lei","Wu, Yingsong","Lin, Guanfeng"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32323974","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1021/acs.analchem.0c00784","locations":["Mouse"],"e_drugs":["Lanthanoid Series Elements"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138493813784576,"score":391.60556}]}